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 Community studies of inﬂ uenza: new knowledge, 
new questions
From the 1940s to the early 1980s, a series of 
prospective, community-based studies provided 
seminal insights into the epidemiology of common 
respiratory infections.1 These observational studies 
consistently showed that inﬂ uenza is a common cause 
of respiratory illness in the community, and the ﬁ ndings 
have been widely used to inform inﬂ uenza control 
policies, such as inﬂ uenza immunisation. In The Lancet 
Respiratory Medicine, the report of the Flu Watch study 
by Andrew Hayward and colleagues2 continues in this 
productive scientiﬁ c tradition but brings it up to date 
through the use of molecular diagnostic techniques. 
Hayward and colleagues recruited and prospectively 
studied ﬁ ve successive cohorts of households across 
England over six periods of inﬂ uenza transmission 
between 2006 and 2011. Participants aged 5 years and 
older provided paired preseason and postseason blood 
samples for inﬂ uenza serology and all participating 
households were contacted weekly to identify any 
cases of cough, cold, sore throat, or “ﬂ u-like illness”. 
Any participant reporting such an illness was asked to 
submit a nasal swab on day 2 of the illness for inﬂ uenza 
virus detection by RT-PCR. A particular strength of 
the Flu Watch study was the analysis of health-care 
consulting behaviours through linkage with the 
participant’s primary health-care records. The study was 
therefore able to estimate the incidence of inﬂ uenza 
infection, the proportion of inﬂ uenza infections that 
were symptomatic, and the proportion of symptomatic 
infections that resulted in consultation with a primary-
care practitioner.
The ﬁ ndings reaﬃ  rm earlier reports that there are 
high rates of serological evidence of inﬂ uenza infection 
without corresponding disease. Hayward and colleagues 
report that roughly 20% of the community shows 
serological evidence of inﬂ uenza infection each season, 
but that most infections (about 75%) are asymptomatic 
or at least so mild that they are not identiﬁ ed through 
weekly active surveillance for respiratory illness. Even 
among individuals with a respiratory illness and PCR-
conﬁ rmed inﬂ uenza infection, classical deﬁ nitions 
of inﬂ uenza-like illness have low sensitivity and only 
17% of individuals consult a medical practitioner. This 
low sensitivity shows that surveillance of medically 
attended illnesses provides a partial and biased picture, 
and is vulnerable to changes in consulting, testing, 
or reporting practices. As such, it is clear that reliable 
estimates of the infection and clinical attack rates during 
the early stages of an inﬂ uenza epidemic requires the 
collection of standardised data across the whole range 
of disease severity, from the community, primary care, 
and secondary care. 
In view of the undoubtedly high rates of subclinical 
inﬂ uenza infection, an important unanswered 
question is the extent to which mild and asymptomatic 
inﬂ uenza infections contribute to transmission. Case-
ascertained household transmission studies have shown 
substantial heterogeneity in the amount and duration 
of viral shedding and, if the area under the curve of viral 
shedding is believed to correlate with transmissibility, 
suggest that 80% of transmission is attributable 
to 20% of clinically symptomatic cases.3 However, 
these estimates are not adjusted for diﬀ ering contact 
patterns of sick and well individuals.4 What is more, 
serologically deﬁ ned infection rates are underestimates, 
because the widely used four-fold or greater rise in 
haemagglutination inhibiting (HI) antibody titre 
between paired serum samples is an overly stringent 
criterion for deﬁ ning infection in epidemiological 
studies5 and a proportion of infected individuals do 
not produce an appreciable HI antibody response.6 
A large number of well individuals mixing widely in the 
community might, even if only mildly infectious, make 
a substantial contribution to onward transmission. This 
might have important implications for the eﬀ ectiveness 
of case isolation and social distancing measures in 
reducing overall transmission rates.
In a global context, the Flu Watch ﬁ ndings are a 
valuable addition to the data accumulating from 
contemporary longitudinal community-based inﬂ uenza 
studies in other countries. Although there is substantial 
consistency in serologically deﬁ ned infection rates per 
season between settings with very diﬀ erent climates 
and socioeconomic conditions, the headline ﬁ gures 
might obscure important heterogeneities in the timing 
and intensity of transmission that may aﬀ ect the 
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Non-cystic ﬁ brosis bronchiectasis is a disorder associated 
with permanent dilatation of proximal cartilage-
containing bronchi; the prevalence of this disorder is 
increasing worldwide.1–3 The pathogenesis of bronchiectasis 
has been described as a vicious circle of events with 
three main components: airway damage, infection, 
and ongoing inﬂ ammation.1,2 The airway inﬂ ammatory 
response is associated with accumulation of various cells 
(eg, neutrophils, lymphocytes, and macrophages) and 
proinﬂ ammatory mediators.1–3 Neutrophilic inﬂ ammation 
can be present even without overt infection, suggesting 
some dysregulation of the innate immune response.4 
Treatment of bronchiectasis is directed at addressing 
the three components of the disease process, and recent 
research has focused on the potential beneﬁ t of various 
anti-inﬂ ammatory therapeutic approaches.1,2,4,5   
Long-term, low-dose macrolide treatment has been 
the most promising anti-inﬂ ammatory strategy, and use 
of these agents in selected patients with bronchiectasis 
is recommended.1,2,4,5 Alternative anti-inﬂ ammatory 
treatments include oral and inhaled corticosteroids, 
oral and inhaled non-steroidal anti-inﬂ ammatory 
drugs, agents targeting speciﬁ c mediators (such as the 
interleukins), and various other novel compounds, but 
with scant evidence of eﬃ  cacy and a paucity of data.1,4,5 
Recent ﬁ ndings suggest that statins could be useful 
in patients with bronchiectasis because of their noted 
anti-inﬂ ammatory and immunomodulatory eﬀ ects,4,6,7 
and at least two clinical studies of atorvastatin are 
ongoing.4 Statins have several modulatory eﬀ ects on 
neutrophils, including decreasing production of reactive 
oxygen species and reduction of neutrophil migration.8 
Furthermore, in people with bronchiectasis, clearance 
of apoptotic cells in the airway is defective, which 
contributes to ongoing airway inﬂ ammation.4,9 Statins 
augment the clearance of apoptotic cells (eﬀ erocytosis) 
both in vivo and in vitro.4,8,10  
In The Lancet Respiratory Medicine, Pallavi Mandal and 
colleagues present the results of a randomised controlled 
trial of atorvastatin in patients with stable bronchiectasis.11 
Patients had clinically signiﬁ cant bronchiectasis, 
conﬁ rmed on chest CT, with cough and sputum 
production in the stable state and two or more chest 
infections in the preceding year. Adults (aged 18–79 years) 
received either atorvastatin 80 mg daily (n=30) or placebo 
(n=30) over a 6-month period. The primary outcome 
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feasibility and impact of interventions. For example, 
in tropical regions the timing of inﬂ uenza epidemics 
is less predictable compared with temperate regions, 
which is problematic for vaccine strain selection and the 
scheduling of immunisation programmes.7 In regions 
where several inﬂ uenza epidemics can occur in a single 
year, the annual (rather than seasonal) rate of infection 
might be higher than in regions that experience only 
one inﬂ uenza season per year. This might aﬀ ect the 
development and maintenance of immunological 
protection against clinically apparent disease and the 
strength of immunological selection pressures acting 
upon the viruses. A direct comparison of data from 
diﬀ erent cohorts would be an invaluable next step 
towards a comprehensive understanding of the global 
epidemiology of inﬂ uenza. 
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